MBX生物公司2024年第四季度GAAP每股收益$(0.47)超过预期$(0.59),截至2024年12月31日持有现金和现金等价物及可转让证券为$262.1M,预计可支持运营至2027年中期

财报速递
17 Mar
MBX生物公司(NASDAQ:MBX)公布季度亏损为每股$(0.47),超过分析师一致预期的$(0.59),超出20.34%。与去年同期每股亏损$(7.74)相比上涨了93.93%。

以上内容来自Benzinga Earnings专栏,原文如下:

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.59) by 20.34 percent. This is a 93.93 percent increase over losses of $(7.74) per share from the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10